Research Article
Characterization of the Lipid Metabolism in Bladder Cancer to Guide Clinical Therapy
Table 3
Mutation atlas differences between high-risk and low-risk patients.
| | Gene | H-wild | H-mutation | L-wild | L-mutation | value |
| | ATAD5 | 195 (97.5%) | 5 (2.5%) | 183 (90.15%) | 20 (9.85%) | 0.004334171 | | PIK3CA | 170 (85%) | 30 (15%) | 151 (74.38%) | 52 (25.62%) | 0.011636589 | | FGFR3 | 181 (90.5%) | 19 (9.5%) | 165 (81.28%) | 38 (18.72%) | 0.011988853 | | HUWE1 | 19 6 (98%) | 4 (2%) | 187 (92.12%) | 16 (7.88%) | 0.012810357 | | SPTAN1 | 188 (94%) | 12 (6%) | 175 (86.21%) | 28 (13.79%) | 0.014308358 | | GON4L | 195 (97.5%) | 5 (2.5%) | 187 (92.12%) | 16 (7.88%) | 0.027357379 | | ALMS1 | 192 (96%) | 8 (4%) | 183 (90.15%) | 20 (9.85%) | 0.034494781 | | RELN | 192 (96%) | 8 (4%) | 183 (90.15%) | 20 (9.85%) | 0.034494781 | | STAG2 | 183 (91.5%) | 17 (8.5%) | 171 (84.24%) | 32 (15.76%) | 0.037673236 | | AHNAK | 189 (94.5%) | 11 (5.5%) | 179 (88.18%) | 24 (11.82%) | 0.037837752 | | MED13 | 191 (95.5%) | 9 (4.5%) | 182 (89.66%) | 21 (10.34%) | 0.040835835 | | UTRN | 191 (95.5%) | 9 (4.5%) | 182 (89.66%) | 21 (10.34%) | 0.040835835 | | C2orf16 | 195 (97.5%) | 5 (2.5%) | 188 (92.61%) | 15 (7.39%) | 0.042331744 | | ATR | 193 (96.5%) | 7 (3.5%) | 185 (91.13%) | 18 (8.87%) | 0.042692803 |
|
|
